secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hemab Therapeutics Holdings, Inc. (COAG)
CIK:        0002114044
Form:       8-K
Filed at:   2026-09-24T20:03:23+00:00
Accession:  0001193125-26-401010
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hemab appoints Keli Walbert to board and audit committee effective Sept 24, 2026
--------------------------------------------------------------------------------

- Keli Walbert elected Class I director, term expiring at 2027 annual meeting; also joins Audit Committee.
- Granted option to purchase 36,000 shares at closing price on Sept 24, 2026; vests monthly over 3 years.
- Annual cash compensation $40,000 (board) plus $10,000 (Audit Committee); equity grants per policy.
- Vesting accelerates in full on change of control; standard indemnification agreement applies.
- No family relationships or reportable transactions with company; no arrangement behind election.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/0001193125-26-401010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/d35700d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-401010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer